References
- Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, . Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488–98.
- Stone JH. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum 2003;48:2299–309.
- Seo P, Stone J. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004;117:39–50.
- Holle JU, Gross WL, Holl-Ulrich K, Ambrosch P, Noelle B, Both M, . Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 2010;69:1934–9.
- Parker NP, Pearlman AN, Conley DB, Kern RC, Chandra RK. The dilemma of midline destructive lesions: a case series and diagnostic review. Am J Otolaryng 2010;31:104–9.
- Al-Hakeem DA, Fedele S, Carlos R, Porter S. Extranodal NK/T-cell lymphoma, nasal type. Oral Oncol 2007;43:4–14.
- Delecluse H-J, Feederle R, O’Sullivan B, Taniere P. Epstein–Barr virus-associated tumours: an update for the attention of the working pathologist. J Clin Pathol 2007;60:1358–64.
- Schwartz EJ, Molina-Kirsch H, Zhao S, Marinelli RJ, Warnke RA, Natkunam Y. Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray. Am J Clin Pathol 2008;130:343–51.
- Rodrigo JP, Suarez C, Rinaldo A, Devaney KO, Carbone A, Barnes L, . Idiopathic midline destructive disease: fact or fiction. Oral Oncol 2005;41:340–8.